Mycophenolate mofetil

Amber

Brand Name(s):CellCept, Myfenax,mycophenolate mofetil

Indication:Inflammatory Arthritis & Connective Tissue Disease for Adult Services, over 16.

Rationale:

Considered:Jul-07

Review Date:Oct-23

Comments:
NICE NG100
Management of Rheumatoid Arthritis in adults
Jul-18
…………………………
Refer to Shared Care documents on the medicines management website
…………………………
Drug Safety Update
Mycophenolate mofetil, mycophenolic acid: new pregnancy-prevention advice for women and men
Full information ca be found at:https://www.gov.uk/drug-safety-update/mycophenolate-mofetil-mycophenolic-acid-new-pregnancy-prevention-advice-for-women-and-men
Dec 2015
…………………………
Drug Safety Update
Mycophenolate mofetil (CellCept) and mycophenolic acid: risk of hypogammaglobulinaemia and risk of bronchiectasis
Full information at:https://www.gov.uk/drug-safety-update/mycophenolate-mofetil-cellcept-and-mycophenolic-acid-risk-of-hypogammaglobulinaemia-and-risk-of-bronchiectasis
January 2015
…………………………
Mycopheonlate salts and brands are not interchangeable. Prescribe as brand. Changes of brand or salt must be supervised by a Consultant.
Dose reduction or discontinuation of mycophenolate mofetil should be considered in patients who develop pure red cell aplasia. Changes to treatment should be done only under specialist supervision to minimise the risk of graft rejection

MHRA Drug Safety Update Volume 2 Issue 12 July 2009